Summary
CGS's LCD L34045 (Non-Invasive Vascular Studies), revised with an effective date of 11/5/2026, expands coverage to include arterial fibromuscular dysplasia (FMD) for non-invasive vascular studies, based on new literature and societal input supporting non-invasive testing for this condition. The revision is described as a coverage expansion rather than a restriction, with all other existing indications and limitations carried over from the prior version.
Get alerts when payers change rules like this one
We check Medicare/CMS - LCD and other payers every day and email you when a change matches your specialty and state.
Get Medicare/CMS - LCD alertsPolicy Monitoring is free. No card required.
What to do
Action · 4 steps
01Already effective 2026-11-05: Billing team should review the revised LCD L34045 and add arterial fibromuscular dysplasia to the clinical indications used in charge entry and documentation checks for cerebrovascular and renal vascular non-invasive studies (for example, duplex ultrasonography of renal arteries), ensuring the ordering provider's note documents the FMD suspicion and how the result will affect management.
02Providers and front desk staff should be informed of the expanded indication so that orders and referrals for these studies include the supporting diagnosis.
03Also confirm claim edits continue to reflect that Z13.9 screening codes remain non-covered and that a referral is on record for each study.
04Watch for CGS's next LCD notice or annual review updates, as the source notes a latest revision (R30) dated 11/05/2026 with no content changes.
Codes mentioned
938809388193882938869389393922939239392493925939269393193970939719397593976939789397993990G0365Z13.9
Original notice
Non-Invasive Vascular Studies
cms.gov · Always check the source before changing claims.